BOULDER, Colo. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment.
Rucaparib is an oral inhibitor of poly ADP-ribose polymerase (PARP), approved in the U.S. in 2016 as Rubraca™ (rucaparib) as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic. Emerging data suggest PARP inhibition may also provide activity in the treatment of metastatic prostate cancers harboring deleterious mutations in BRCA1/2 and ATM or other human genes associated with DNA damage repair. These mutations may be germline (inherited) or somatic (acquired).
Strata Oncology is conducting the Strata Trial, an observational study that provides next-generation sequencing at no cost to all advanced cancer patients at its affiliated cancer centers and hospitals. Strata then refers patients with selected mutations to physicians involved in its pharmaceutical partners’ targeted clinical trials. Strata seeks to fulfill the promise of precision medicine by improving the number of patients identified with specific mutations appropriate for ongoing clinical trials.
Under the terms of the agreement, Strata will exclusively refer BRCA and ATM-mutated advanced prostate cancer patients for consideration of enrollment to Clovis’ TRITON2 and TRITON3 clinical trials of rucaparib. The Strata Trial is available at an expanding network of select cancer centers and hospitals nationwide.
“We’re delighted to work with Clovis Oncology in advancing development of their highly promising drug rucaparib for prostate cancer patients,” said Dan Rhodes, Ph.D., CEO of Strata Oncology. “We are confident that we will identify a number of mutant BRCA and ATM prostate cancer patients through the Strata Trial, and accelerate enrollment in the TRITON2 and TRITON3 clinical trials.”
“Following rucaparib’s initial U.S. approval in ovarian cancer, we are committed to rapidly enrolling additional trials and expanding rucaparib development into broader indications, including prostate,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Through our work with Strata, we seek to address the significant challenge of identifying and enrolling the right patients – in this case, patients with advanced prostate cancer who possess mutations of BRCA and/or ATM – in support of advancing our precision medicine clinical trials and potentially providing rucaparib to a broader population of patients who may benefit.”
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. For more information visit www.clovisoncology.com.
About Strata Oncology
Strata Oncology is a precision medicine company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials. The Strata Trial provides no-cost tumor sequencing to patients with advanced cancer, while offering pharmaceutical companies exclusive access to stratified patient populations to shorten clinical development timelines. Strata aims to accelerate the approval of new medicines for cancer patients by bringing together a collaborative network of key stakeholders including patients, providers and pharmaceutical companies. For more information visit www.strataoncology.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the market potential of our approved drug, including the performance of our sales and marketing efforts and the success of competing drugs, the performance of our third-party manufacturers, our clinical development programs for our drug candidates, the corresponding development pathways of our companion diagnostics, actions by the FDA, the EMA or other regulatory authorities regarding whether to approve drug applications that may be filed, as well as their decisions regarding drug labeling, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.
